Emissary Technology Key to Enrolling First Patient Within 7 Days of FDA Approval of a Dialysis Graft Trial

Emissary Inc. has been selected by Novoste Corporation (Nasdaq:NOVT) to collaborate on monitoring and clinical trial management of Novoste's BRAVO (Beta Radiation for treatment of Arterial-Venous graft Outflow) clinical trial.

Nike Sneakers StoreAir Jordan 1 Low GS Ice Cream Drip CW7104-601 Release Date Info

Read more: Emissary Technology Key to Enrolling First Patient Within 7 Days of FDA Approval of a Dialysis...

Emissary Key to Radiation Study Success

Looking to increase the efficiency of its recently approved beta radiation trial, Novoste (Norcross, Georgia) selected contract research organization Emissary (Austin, Texas) to run the show. Emissary's TeamTrials electronic data capture technology will be used to monitor and manage the BRAVO (Beta Radiation for treatment of Arterial-Venous dialysis graft Outflow) clinical trial.

best Running shoes brandGucci x The North Face Release Information

Read more: Emissary Key to Radiation Study Success

More Trials & Tribulations for Clinical Monitoring

Clinical trial litigation is on the rise in the drug arena, and the effects could soon spread to the device industry. The Legal Times (Washington, DC) has reported that lawsuits are increasing and often pursue every person and institution in their paths. If device manufacturers want to avoid legal action, they need to protect themselves by making sure they’re not cutting corners.

The first step is to hire the proper staff to monitor clinical trials, says Steven Mayo, president of Austin, TX–based Emissary International, a contract research organization. "America seems to be in a lawsuit craze, and the number of high-profile lawsuits seems to be increasing," says Mayo. "The class-action lawsuit trend is a negative [development] that’s really affecting [the device] industry."

Sports ShoesNike

Read more: More Trials & Tribulations for Clinical Monitoring

Clinical Trial Accrual Hampered by Many Factors

In recent years, cancer patients are more knowledgeable and willing to participate in clinical trials, but issues pertaining to physician enthusiasm, design requirements, and enrollment procedures now pose large barriers to patient accrual, finds two new Cancer studies. Since previous research has predominantly focused on patient and physician perspectives, Canadian researchers interviewed clinical research associates (CRAs), whose work spans all stages of clinical trials, to gain new insight into the factors influencing enrollment. The CEO of an Austin, Texas-based contract research organization (CRO), which designs trials and staffs CRAs, told the Watch (9/24/02) that the strict participation guidelines for oncology-related clinical trials make meeting accrual goals for experimental cancer therapies particularly difficult.

best Running shoes brandPatike – Nike Air Jordan, Premium, Retro Klasici, Sneakers

Read more: Clinical Trial Accrual Hampered by Many Factors

Emissary Presents at Southwest Equity Capital Summit

AUSTIN, Texas -- Emissary Inc. today announced that it will participate in the 2002 Southwest Equity Capital Summit organized by the Capital Network October 2-3 in Richardson, Texas. Steven Mayo, founder and CEO of Emissary, will present the company's plans to streamline drug and medical device research studies with a new Web-based software initiative.

buy shoesNike Air Force 1 07 Khaki Dark Green Medium Olive /Black-Starfish

Read more: Emissary Presents at Southwest Equity Capital Summit